Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$127.12M-26.2%-$104.9M-20.7%-$120.36M-51.0%-$34.6M+54.9%-$100.74M-55.0%
$117K+3.5%$121K+3.4%$120K-2.4%$110K-15.4%$113K-20.4%
$16.98M+56.6%$13.39M+31.0%$11.99M+33.6%$11.25M+29.0%$10.84M-7.8%
-$105.32M-39.7%-$119.65M-29.1%-$23.75M+67.6%-$84.61M-25.0%-$75.37M-63.6%
$1.31M+3,010%$23K-73.3%$240K+111%$127K-56.7%$42K-59.6%
-$231.16M-405%$77.26M-22.8%-$339.42M-439%$126.08M+249%$75.72M
$7.22M$7.22M$7.22M
$325.12M+42,455%$6.36M-31.0%$405.91M+1,043%$10.86M-95.6%$764K+607%
-$11.36M-1,124%-$36.04M-317%$42.74M+142%$52.32M-43.5%$1.11M-93.1%
-$106.63M-41.4%-$119.68M-29.0%-$23.99M+67.3%-$84.74M-24.6%-$75.42M-63.4%

FAQ

How much cash does Viridian Therapeutics, Inc. generate?
Viridian Therapeutics, Inc. (VRDN) generated -$333.3M in operating cash flow over the trailing twelve months.
What is Viridian Therapeutics, Inc.'s free cash flow?
After $1.7M of capital expenditures, Viridian Therapeutics, Inc.'s free cash flow was -$335.0M over the trailing twelve months, down 8.2% year over year.
Where does Viridian Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.